CGBIO signs $500M deal with Japan's Nippon Zoki for Novosis Putty

South Korean biopharmaceutical firm CGBIO signed an exclusive agreement worth $500 million with Japan's Nippon Zoki Pharmaceutical to develop and commercialize Novosis Putty, a bone graft treatment for lumbar spine degeneration.

“CGBIO has entered into an exclusive agreement worth $500 million with Japan's leading firm Nippon Zoki Pharmaceutical to develop and commercialize Novosis Putty”cgbio.co.kr

• 1 source
• cgbio.co.krCGBIO signs $500 million deal with Japan’s Nippon Zoki for NOVOSIS Putty – CGBIO_ENcgbioSep 23, 2019

Summarized from public sources; check the original articles before acting on it.